Comparison tool

Setmelanotide vs Liraglutide side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

SetmelanotideLiraglutide

Share this peptide comparison

Property	Setmelanotide	Liraglutide
Category	Weight Loss	Weight Loss
Also known as	Imcivree, RM-493	Victoza, Saxenda
FDA approved	Yes	Yes
Clinical status	FDA approved for specified rare obesity indications including BBS, POMC/PCSK1/LEPR deficiency, and acquired hypothalamic obesity. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	FDA approved for diabetes as Victoza and weight loss as Saxenda; source also reports Teva generic Saxenda launched Aug 2025. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Genetic obesity disorders and rare metabolic conditions	Weight management, diabetes control, appetite suppression
How it works	Setmelanotide is reported as a melanocortin-4 receptor agonist. The supplied mechanism evidence places MC4R downstream of leptin and POMC signaling in hypothalamic appetite regulation. For rare conditions such as POMC, PCSK1, or LEPR deficiency, the source states that upstream signaling can be impaired while MC4R remains a target; direct MC4R agonism is therefore presented as the rationale for its narrow genetic-obesity use.	Liraglutide is reported to act as a GLP-1 receptor agonist. The source describes glucose-dependent pancreatic insulin signaling, reduced glucagon activity, delayed gastric emptying, and central appetite-related GLP-1 receptor activity in the hypothalamus as mechanisms relevant to glucose control and satiety.
Typical dosing	2-3 mg daily · Once daily · Subcutaneous injection	1.8-3 mg daily · Once daily · Subcutaneous injection daily
Research dosing	2-3 mg daily in adults · Long-term / chronic use · Subcutaneous injection daily	0.6mg daily (starting) · Once daily · Long-term / chronic use · Subcutaneous injection daily
Typical duration	Long-term / chronic use	Long-term / chronic use
Administration	Subcutaneous injection	Subcutaneous injection daily
Timing	Beginning of the day Without regard to meals	Morning or evening, consistent daily With or without food
Evidence level	FDA Approved	FDA Approved
Possible side effects	Skin hyperpigmentation (Source reports 67-83% frequency.) Injection-site reactions (Reported in source side-effect list.) Nausea (Reported in source side-effect list.) +4 more Spontaneous erections in males (Reported in source side-effect list.) Priapism risk (Reported as a risk in source side-effect list.) Depression risk (Reported as a risk in source side-effect list.) Headache (Reported in the source research summary.)	Nausea (Common; source highlights gastrointestinal effects especially during dose escalation.) Vomiting (Reported gastrointestinal side effect.) Diarrhea (Reported gastrointestinal side effect.) +7 more Constipation (Reported side effect.) Headache (Reported side effect.) Hypoglycemia (Reported with insulin or sulfonylureas.) Pancreatitis (Reported serious adverse event.) Gallbladder disease (Reported serious adverse event.) Acute kidney injury (Reported serious adverse event.) Thyroid C-cell tumors (Boxed warning; source says this is based on rodent studies and that a clear human link has not been established.)
Research summary	The supplied source summarizes clinical evidence as narrow but strong for rare disease populations. It reports pivotal open-label, single-arm phase 3 studies in POMC and LEPR deficiency, with at least 10% weight loss at about one year in 80% of POMC participants and 45% of LEPR participants, plus reduced hunger scores. The source also cites a randomized placebo-controlled phase 3 study for Bardet-Biedl syndrome and a 2024 VENTURE open-label study including children as young as two. Because the conditions are rare, the evidence base is described as small and indication-specific rather than broadly applicable to common obesity.	The source characterizes liraglutide evidence as human clinical evidence rather than preliminary research. It reports that the LEADER trial enrolled 9,340 high-risk participants with type 2 diabetes and found cardiovascular death, heart attack, or stroke occurred in 13.0% with liraglutide versus 14.9% with placebo, published in the New England Journal of Medicine in 2016. For weight outcomes, the source cites the SCALE program, where adults without diabetes lost about 8% of body weight at 56 weeks on the 3.0 mg Saxenda dose. It also notes that nausea, vomiting, and diarrhea are common, particularly during dose escalation, and that labeling includes a boxed warning for thyroid C-cell tumors based on rodent findings without a confirmed human link.
References	The Lancet Diabetes & Endocrinology PubMed Central +2 more The Lancet Diabetes & Endocrinology Current Opinion in Endocrinology, Diabetes and Obesity	PubMed New England Journal of Medicine +2 more Drugs.com Pharmacy Times
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Setmelanotide

Liraglutide

Category

Weight Loss

Also known as

Imcivree, RM-493

Victoza, Saxenda

FDA approved

Yes

Clinical status

FDA approved for specified rare obesity indications including BBS, POMC/PCSK1/LEPR deficiency, and acquired hypothalamic obesity.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

FDA approved for diabetes as Victoza and weight loss as Saxenda; source also reports Teva generic Saxenda launched Aug 2025.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Genetic obesity disorders and rare metabolic conditions

Weight management, diabetes control, appetite suppression

How it works

Setmelanotide is reported as a melanocortin-4 receptor agonist. The supplied mechanism evidence places MC4R downstream of leptin and POMC signaling in hypothalamic appetite regulation. For rare conditions such as POMC, PCSK1, or LEPR deficiency, the source states that upstream signaling can be impaired while MC4R remains a target; direct MC4R agonism is therefore presented as the rationale for its narrow genetic-obesity use.

Liraglutide is reported to act as a GLP-1 receptor agonist. The source describes glucose-dependent pancreatic insulin signaling, reduced glucagon activity, delayed gastric emptying, and central appetite-related GLP-1 receptor activity in the hypothalamus as mechanisms relevant to glucose control and satiety.

Typical dosing

2-3 mg daily · Once daily · Subcutaneous injection

1.8-3 mg daily · Once daily · Subcutaneous injection daily

Research dosing

2-3 mg daily in adults · Long-term / chronic use · Subcutaneous injection daily

0.6mg daily (starting) · Once daily · Long-term / chronic use · Subcutaneous injection daily

Typical duration

Long-term / chronic use

Administration

Subcutaneous injection

Subcutaneous injection daily

Timing

Beginning of the day

Without regard to meals

Morning or evening, consistent daily

With or without food

Evidence level

FDA Approved

Possible side effects

Skin hyperpigmentation (Source reports 67-83% frequency.)
Injection-site reactions (Reported in source side-effect list.)
Nausea (Reported in source side-effect list.)

+4 more

Spontaneous erections in males (Reported in source side-effect list.)
Priapism risk (Reported as a risk in source side-effect list.)
Depression risk (Reported as a risk in source side-effect list.)
Headache (Reported in the source research summary.)

Nausea (Common; source highlights gastrointestinal effects especially during dose escalation.)
Vomiting (Reported gastrointestinal side effect.)
Diarrhea (Reported gastrointestinal side effect.)

+7 more

Constipation (Reported side effect.)
Headache (Reported side effect.)
Hypoglycemia (Reported with insulin or sulfonylureas.)
Pancreatitis (Reported serious adverse event.)
Gallbladder disease (Reported serious adverse event.)
Acute kidney injury (Reported serious adverse event.)
Thyroid C-cell tumors (Boxed warning; source says this is based on rodent studies and that a clear human link has not been established.)

Research summary

The supplied source summarizes clinical evidence as narrow but strong for rare disease populations. It reports pivotal open-label, single-arm phase 3 studies in POMC and LEPR deficiency, with at least 10% weight loss at about one year in 80% of POMC participants and 45% of LEPR participants, plus reduced hunger scores. The source also cites a randomized placebo-controlled phase 3 study for Bardet-Biedl syndrome and a 2024 VENTURE open-label study including children as young as two. Because the conditions are rare, the evidence base is described as small and indication-specific rather than broadly applicable to common obesity.

The source characterizes liraglutide evidence as human clinical evidence rather than preliminary research. It reports that the LEADER trial enrolled 9,340 high-risk participants with type 2 diabetes and found cardiovascular death, heart attack, or stroke occurred in 13.0% with liraglutide versus 14.9% with placebo, published in the New England Journal of Medicine in 2016. For weight outcomes, the source cites the SCALE program, where adults without diabetes lost about 8% of body weight at 56 weeks on the 3.0 mg Saxenda dose. It also notes that nausea, vomiting, and diarrhea are common, particularly during dose escalation, and that labeling includes a boxed warning for thyroid C-cell tumors based on rodent findings without a confirmed human link.

References

The Lancet Diabetes & Endocrinology PubMed Central

+2 more

The Lancet Diabetes & Endocrinology Current Opinion in Endocrinology, Diabetes and Obesity

PubMed New England Journal of Medicine

+2 more

Drugs.com Pharmacy Times

Full profile

View Details